Skip to main content
SpringerLink
Log in

Primary Urethral Melanoma

  • Chapter
  • First Online:
Rare Genitourinary Tumors

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. El-Safadi S, Estel R, Mayser P, Muenstedt K. Primary malignant melanoma of the urethra: a systematic analysis of the current literature. Arch Gynecol Obstet. 2014;289(5):935–43.

    Article  PubMed  Google Scholar 

  2. Oliva E, Quinn TR, Amin MB, Eble JN, Epstein JI, Srigley JR, et al. Primary malignant melanoma of the urethra: a clinicopathologic analysis of 15 cases. Am J Surg Pathol. 2000;24(6):785–96.

    Article  CAS  PubMed  Google Scholar 

  3. Papes D, Altarac S. Melanoma of the female urethra. Med Oncol. 2013;30(1):329-012-0329-2. Epub 2012 Dec 18.

    Google Scholar 

  4. DiMarco DS, DiMarco CS, Zincke H, Webb MJ, Keeney GL, Bass S, et al. Outcome of surgical treatment for primary malignant melanoma of the female urethra. J Urol. 2004;171(2 Pt 1):765–7.

    Article  PubMed  Google Scholar 

  5. Nguyen AT, Kavolius JP, Russo P, Grimaldi G, Katz J, Brady MS. Primary genitourinary melanoma. Urology. 2001;57(4):633–8.

    Article  CAS  PubMed  Google Scholar 

  6. Chang AE, et al. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–78.

    Article  CAS  PubMed  Google Scholar 

  7. Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a case-based review of the literature. Oncologist. 2010;15(7):772–81.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  PubMed  Google Scholar 

  9. Papes D, Altarac S, Arslani N, Rajkovic Z, Antabak A, Cacic M. Melanoma of the glans penis and urethra. Urology. 2014;83(1):6–11.

    Article  PubMed  Google Scholar 

  10. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131–49. quiz 182–4.

    Article  PubMed  Google Scholar 

  11. van Geel AN, den Bakker MA, Kirkels W, Horenblas S, Kroon BB, de Wilt JH, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology. 2007;70(1):143–7.

    Article  PubMed  Google Scholar 

  12. Elder DE, Jucovy PM, Tuthill RJ, Clark Jr WH. The classification of malignant melanoma. Am J Dermatopathol. 1980;2(4):315–20.

    Article  CAS  PubMed  Google Scholar 

  13. Paladugu RR, Winberg CD, Yonemoto RH. Acral lentiginous melanoma. A clinicopathologic study of 36 patients. Cancer. 1983;52(1):161–8.

    Article  CAS  PubMed  Google Scholar 

  14. Oldbring J, Mikulowski P. Malignant melanoma of the penis and male urethra. Report of nine cases and review of the literature. Cancer. 1987;59(3):581–7.

    Article  CAS  PubMed  Google Scholar 

  15. Morita T, Suzuki H, Goto K, Hirota N, Tokue A. Primary malignant melanoma of male urethra with fistula formation. Urol Int. 1991;46(1):114–5.

    Article  CAS  PubMed  Google Scholar 

  16. Bostwick DG, Eble JN. Neoplasms of the prostate. Urol Surg Pathol. 1 ed. St. Louis: Mosby-Yearbook Inc. 1997;373–5.

    Google Scholar 

  17. Tetzlaff MT, Torres-Cabala CA, Pattanaprichakul P, Rapini RP, Prieto VG, Curry JL. Emerging clinical applications of selected biomarkers in melanoma. Clin Cosmet Investig Dermatol. 2015;8:35–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC, et al. Management of advanced primary urethral carcinomas. BJU Int. 2014;114(1):25–31.

    Article  PubMed  Google Scholar 

  19. Wood HM, Angermeier KW. Anatomic considerations of the penis, lymphatic drainage, and biopsy of the sentinel node. Urol Clin North Am. 2010;37(3):327–34.

    Article  PubMed  Google Scholar 

  20. McAninch JW, Lue TF. Smith & Tanagho’s general urology. 18th ed. New York: McGraw-Hill; 2013. p. 14–5.

    Google Scholar 

  21. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011;65(5):1032–47.

    Article  PubMed  Google Scholar 

  22. Johnson TM, Bradford CR, Gruber SB, Sondak VK, Schwartz JL. Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol. 2004;140(1):107–13.

    Article  PubMed  Google Scholar 

  23. Sanchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol. 2005;173(6):1958–65.

    Article  CAS  PubMed  Google Scholar 

  24. Lont AP, Horenblas S, Tanis PJ, Gallee MP, van Tinteren H, Nieweg OE. Management of clinically node negative penile carcinoma: improved survival after the introduction of dynamic sentinel node biopsy. J Urol. 2003;170(3):783–6.

    Article  CAS  PubMed  Google Scholar 

  25. Sibon C, Chagnon S, Tchakerian A, Bafounta ML, Longvert C, Clerici T, et al. The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. Melanoma Res. 2007;17(4):233–7.

    Article  PubMed  Google Scholar 

  26. van Rijk MC, Teertstra HJ, Peterse JL, Nieweg OE, Olmos RA, Hoefnagel CA, et al. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol. 2006;13(11):1511–6.

    Article  PubMed  Google Scholar 

  27. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer. 2000;88(1):88–94.

    Article  CAS  PubMed  Google Scholar 

  29. Oxley JD, Corbishley C, Down L, Watkin N, Dickerson D, Wong NA. Clinicopathological and molecular study of penile melanoma. J Clin Pathol. 2012;65(3):228–31.

    Article  CAS  PubMed  Google Scholar 

  30. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163(2):238–56.

    Article  CAS  PubMed  Google Scholar 

  31. Allan CP, Hayes AJ, Thomas JM. Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin. ANZ J Surg. 2008;78(11):982–6.

    Article  PubMed  Google Scholar 

  32. van der Ploeg AP, van Akkooi AC, Schmitz PI, van Geel AN, de Wilt JH, Eggermont AM, et al. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol. 2011;18(12):3300–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Glover AR, Allan CP, Wilkinson MJ, Strauss DC, Thomas JM, Hayes AJ. Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis. Br J Surg. 2014;101(7):811–9.

    Article  CAS  PubMed  Google Scholar 

  34. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Book  Google Scholar 

  35. Eggermont AM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.

    Article  CAS  PubMed  Google Scholar 

  36. Kirkwood JM, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperation Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.

    CAS  PubMed  Google Scholar 

  37. Eggermont AM, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–26.

    Article  CAS  PubMed  Google Scholar 

  38. Lian B, et al. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013;19(16):4488–98.

    Article  CAS  PubMed  Google Scholar 

  39. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–256.

    Article  CAS  PubMed  Google Scholar 

  41. Postow MA, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013;18(6):726–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Del Vecchio M, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pre-treated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50(1):121–7.

    Article  PubMed  Google Scholar 

  43. Alexander M, et al. Ipilimumab in pretreated patients with unresectable cutaneous, uveal, and mucosal melanoma. Med J Aust. 2014;201(1):49–53.

    Article  PubMed  Google Scholar 

  44. National Comprehensive Cancer Network. NCCN guidelines—melanoma. V3.2015. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed 16 Jul 2015.

  45. Opdivo® (Nivolumab) US prescribing information 2015. Bristol-Myers Squibb. Princeton. http://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed 16 July 2015.

  46. Min L, et al. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2013;2(1):15–8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Ohtsuka M, et al. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol. 2015; Published online 15 Apr 2015.

    Google Scholar 

  48. Long GV, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; Published online 29 May 2015.

    Google Scholar 

  49. Robert C, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.

    Article  PubMed  Google Scholar 

  50. Larkin J, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.

    Article  PubMed  Google Scholar 

  51. Carvajal RD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hodi FS, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Guo J, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification. J Clin Oncol. 2011;29(21):2904–9.

    Article  CAS  PubMed  Google Scholar 

  54. Yi JH, et al. Dacarbazine-based chemotherapy as first-line treatment in non-cutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011;21(3):223–7.

    Article  CAS  PubMed  Google Scholar 

  55. Bartell HL, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck. 2008;30(12):1592–8.

    Article  PubMed  Google Scholar 

  56. Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res. 2004;14(6):517–20.

    Article  CAS  PubMed  Google Scholar 

  57. Kim KB, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004;100(7):1478–83.

    Article  CAS  PubMed  Google Scholar 

  58. Chang W, et al. Effect of paclitaxel/carboplatin salvage chemotherapy in non-cutaneous versus cutaneous metastatic melanoma. Melanoma Res. 2013;23(2):147–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1373, Houston, TX, 77030, USA

    Austen Slade BS & Curtis A. Pettaway MD

  2. Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA

    Michael Tetzlaff MD, PhD

  3. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA

    Van Anh Trinh PharmD & Wen-Jen Hwu MD, PhD

Authors
  1. Austen Slade BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Tetzlaff MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Van Anh Trinh PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-Jen Hwu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Curtis A. Pettaway MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Curtis A. Pettaway MD .

Editor information

Editors and Affiliations

  1. Department of Oncology, Mayo Clinic, Division of Medical Oncology, Rochester, Minnesota, USA

    Lance Pagliaro

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Slade, A., Tetzlaff, M., Trinh, V.A., Hwu, WJ., Pettaway, C.A. (2016). Primary Urethral Melanoma. In: Pagliaro, L. (eds) Rare Genitourinary Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-30046-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30046-7_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30044-3

  • Online ISBN: 978-3-319-30046-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation